Oppenheimer Keeps a Hold Rating on Stryker

By Ryan Adsit

In a report released today, Steven Lichtman from Oppenheimer reiterated a Hold rating on Stryker (NYSE: SYK). The company’s shares opened today at $142.65, close to its 52-week high of $145.62.

According to TipRanks.com, Lichtman is ranked 0 out of 5 stars with an average return of -4.5% and a 55.4% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Integra Lifesciences.

Stryker has an analyst consensus of Hold, with a price target consensus of $141.

The company has a one year high of $145.62 and a one year low of $106.48. Currently, Stryker has an average volume of 1.05M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stryker Corp. is engaged in providing medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The Medsurg segment deals with surgical instruments and equipment, endoscopy, patient handling, and reprocessed medical devices. The Neurotechnology and Spine segment pertains to spinal implants and neurovascular products. The company was founded by Homer H. Stryker in 1941 and is headquartered in Kalamazoo, MI.